ArticleEMBO reports2026
COP9 signalosome regulates EGFR and Notch signaling during myeloid-type progenitor cell fate decision in Drosophila.
Article in EMBO reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The COP9 signalosome (CSN) plays crucial roles in various cellular processes, including cell proliferation and DNA repair, by regulating Cullin-RING ubiquitin ligases that influence protein stability. However, the mechanism by which CSN regulates multiple signaling pathways in stem and progenitor cells for different cell fate decisions remains elusive. Here, we examine the role of the CSN in determining the fate of blood progenitors within the developing Drosophila larval hematopoietic organ, the lymph gland, using in vivo genetics and cell biological methods. We find that CSN-deneddylated, inactive Cullin-1 regulates the differentiation of intermediate progenitors in the lymph glands to generate a correct ratio of plasmatocytes and crystal cells. CSN also controls Serrate activation, which triggers Notch signaling in neighboring cells, leading them to become crystal cells. Moreover, CSN modulates epidermal growth factor receptor (EGFR) signaling, which regulates Notch signaling in intermediate progenitors. Our study reveals that CSN-mediated regulation of EGFR and Notch signaling is crucial for determining the cell fate of myeloid-type blood progenitors, making the lymph gland a convenient model to understand human disease caused by dysregulated EGFR and Notch signaling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.